Browsing by Author "Ozyar, Enis"

Now showing 1 - 4 of 4

Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study-IMET, Protocol MF 14-02 (vol 29, pg 6327, 2022)
(2023) Soran, Atilla; Ozbas, Serdar; Ozcinar, Beyza; Isik, Arda; Dogan, Lutfi; Senol, Kazim; Dag, Ahmet; Karanlik, Hasan; Aytac, Ozgur; Cakmak, Guldeniz Karadeniz; Dalci, Kubilay; Dogan, Mutlu; Sezer, Yavuz Atakan; Gokgoz, Sehsuvar; Ozyar, Enis; Sezgin, Efe; 36484906
Intervention to hepatic and pulmonary METastases in breast cancer patients: Prospective, multi-institutional registry study-IMET; Protocol MF 14-02
(2022) Soran, Atilla; Ozbas, Serdar; Ozcinar, Beyza; Isik, Arda; Dogan, Lutfi; Senol, Kazim; Dag, Ahmet; Karanlik, Hasan; Aytac, Ozgur; Cakmak, Guldeniz Karadeniz; Dalci, Kubilay; Dogan, Mutlu; Sezer, Yavuz Atakan; Gokgoz, Mustafa Sehsuvar; Ozyar, Enis; Sezgin, Efe
The Potential Role Of MR-Guided Adaptive Radiotherapy In Pediatric Oncology: Results From A SIOPE-COG Survey
(2021) Seravalli, Enrica; Kroon, Petra S.; Buatti, John M.; HalL, Matthew D.; Mandeville, Henry C.; Marcus, Karen J.; Onal, Cem; Ozyar, Enis; Paulino, Arnold C.; Paulsen, Frank; Saunders, Daniel; Tsang, Derek S.; Wolden, Suzanne L.; Janssens, Geert O.; 34159265
Background and purpose: Magnetic resonance guided radiotherapy (MRgRT) has been successfully implemented for several routine clinical applications in adult patients. The purpose of this study is to map the potential benefit of MRgRT on toxicity reduction and outcome in pediatric patients treated with curative intent for primary and metastatic sites. Materials and methods: Between May and August 2020, a survey was distributed among SIOPE- and COG-affiliated radiotherapy departments, treating at least 25 pediatrics patients annually and being (candidate) users of a MRgRT system. The survey consisted of a table with 45 rows (clinical scenarios for primary (n = 28) and metastatic (n = 17) tumors) and 7 columns (toxicity reduction, outcome improvement, PTV margin reduction, target volume daily adaptation, online re-planning, intrafraction motion compensation and on-board functional imaging) and the option to answer by 'yes/no'. Afterwards, the Dutch national radiotherapy cohort was used to estimate the percentage of pediatric treatments that may benefit from MRgRT. Results: The survey was completed by 12/17 (71% response rate) institutions meeting the survey inclusion criteria. Responders indicated an 'expected benefit' from MRgRT for toxicity/outcome in 7% (for thoracic lymphomas and abdominal rhabdomyosarcomas)/0% and 18% (for mediastinal lymph nodes, lymph nodes located in the liver/splenic hilum, and liver metastases)/0% of the considered scenarios for the primary and metastatic tumor sites, respectively, and a 'possible benefit' was estimated in 64%/46% and 47%/59% of the scenarios. When translating the survey outcome into a clinical perspective a toxicity/outcome benefit, either expected or possible, was anticipated for 55%/24% of primary sites and 62%/38% of the metastatic sites. Conclusion: Although the benefit of MRgRT in pediatric radiation oncology is estimated to be modest, the potential role for reducing toxicity and improving clinical outcomes warrants further investigation. This fits best within the context of prospective studies or registration trials.
Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience
(2018) Atalar, Banu; Ozsahin, Mahmut; Call, Jason; Napieralska, Aleksandra; Kamer, Serra; Villa, Salvador; Erpolat, Petek; Negretti, Laura; Lassen-Ramshad, Yasmin; Onal, Cem; Akyurek, Serap; Ugurluer, Gamze; Baumert, Brigitta G.; Servagi-Vernat, Stephanie; Miller, Robert C.; Ozyar, Enis; Sio, Terence T.; https://orcid.org/0000-0002-2742-9021; 29373196; D-5195-2014
Background and purpose: The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network. Material and methods: Thirteen institutions enrolled 206 MB patients who underwent postoperative radiotherapy (RT) between 1976 and 2014. Log-rank univariate and Cox-modeled multivariate analyses were used to analyze data collected. Results: Median patient age was 29 years; follow-up was 31 months. All patients had the tumor resected; surgery was complete in 140 (68%) patients. Postoperative RT was given in 202 (98%) patients, and 94% received craniospinal irradiation (CSI) and, usually, a posterior fossa boost. Ninety-eight (48%) patients had chemotherapy, mostly cisplatin and vincristine-based. The 10-year local control, overall survival, and disease-free survival rates were 46%, 51%, and 38%, respectively. In multivariate analyses, Karnofsky Performance Status (KPS) >= 80 and CSI were significant for disease-free and overall survival (P <= .04 for all); receiving chemotherapy and KPS >= 80 correlated with better local-control rates. Conclusions: Patients with high KPS who received CSI had better rates of disease-free and overall survival. Chemotherapy was associated with better local control. These results may serve as a benchmark for future studies designed to improve outcomes for adults with medulloblastoma. (C) 2018 Elsevier B. V. All rights reserved. Radiotherapy and Oncology 127 (2018) 96-102